MedTrace Logo

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

NCT00503295 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2014-10-02

No results posted yet for this study

Summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus is safe and effective in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.

Conditions

  • Osteosarcoma
  • Ewing Sarcoma Family Tumors
  • Malignant Fibrous Histiocytoma
  • Sarcoma, Synovial
  • Fibrosarcoma
  • Leiomyosarcoma

Interventions

BIOLOGICAL

REOLYSIN®

REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.

Sponsors & Collaborators

Principal Investigators

  • Karl Mettinger, MD, PhD · Oncolytics Biotech

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2011-02-28
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00503295 on ClinicalTrials.gov